Inhibitors | Comment | Organism | Structure |
---|---|---|---|
farnesol | dead-end inhibitor | Homo sapiens |
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
55300 | - |
mass spectroscopy | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | Q9UHG3 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
blood plasma | VLDL contains a greater protein content of PCL1 than LDL or HDL | Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
farnesyl-L-cysteine + O2 + H2O | - |
Homo sapiens | farnesal + L-cysteine + H2O2 | - |
? |
Synonyms | Comment | Organism |
---|---|---|
PCL1 | - |
Homo sapiens |
prenylcysteine lyase | - |
Homo sapiens |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
23 | - |
assay at | Homo sapiens |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
FAD | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
metabolism | liquid-phase IEF is used to resolve LDL proteins into well-defined fractions on the basis of pI. Besides known LDL-associated proteins, the presence of proteins not previously described to reside in LDL, including prenylcysteine lyase (PCL1) is shown. The finding that an enzyme associated with atherogenic lipoproteins can itself generate an oxidant suggests that PCL1 may play a significant role in atherogenesis | Homo sapiens |